预约演示
更新于：2025-03-26
Trinitrate
三硝酸酯
更新于：2025-03-26
概要
基本信息
简介三硝酸酯是默克公司研制的一种小分子药物，于 1983 年首次进入医药市场。该药物具有双重属性：它可作为可溶性鸟苷酸环化酶 (sGC) 的催化剂，以及一氧化氮供体。硝酸甘油的适用范围广泛，包括心绞痛、勃起功能障碍、疼痛和肛裂。通过激发 sGC 刺激和释放一氧化氮，这种多用途药物会导致血管舒张，最终缓解上述疾病。 |
药物类型 小分子化药 |
别名 1,2,3-propanetrioltrinitrate、1,2,3-propanetriyl nitrate、Anrecta + [43] |
靶点 |
作用方式 刺激剂、供体 |
作用机制 ALDH2刺激剂(乙醛脱氢酶刺激剂)、一氧化氮供体 |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C3H5N3O9 |
InChIKeySNIOPGDIGTZGOP-UHFFFAOYSA-N |
CAS号55-63-0 |
关联
300
项与 三硝酸酯 相关的临床试验NCT06859554
Assessing the Therapeutic Efficacy and Safety Profile of Glyceryl Trinitrate (GTN) and Nifedipine Ointments in Acute Anal Fissure Treatment: a Parallel-arm Clinical Trial
CTR20250093
评估受试制剂硝酸甘油舌下片（规格：0.6 mg）与参比制剂Nitrostat®（规格：0.6 mg）在健康成年受试者空腹状态下的单中心、开放、随机、单剂量、四周期、两序列、完全重复交叉生物等效性研究
NCT06785337
"The Effect of Inhaled Nitroglycerin on Improving Respiratory Failure in COPD Patients Admitted to Adult Intensive Care Unit"
100 项与 三硝酸酯 相关的临床结果
登录后查看更多信息
100 项与 三硝酸酯 相关的转化医学
登录后查看更多信息
100 项与 三硝酸酯 相关的专利（医药）
登录后查看更多信息
21,055
项与 三硝酸酯 相关的文献（医药）2025-12-01Techniques in Coloproctology
The use of a methylene blue and glyceryl trinitrate-based cream for the treatment of chronic anal fissures: a phase II randomized pilot trial from a referral coloproctological unit
Article
作者: Laforgia, R ; Lobascio, P ; Pezzolla, A ; Tomasicchio, G ; Cassetta, N ; Altomare, D F ; Gallo, G
BACKGROUND:
Chronic anal fissures (CAFs) are the second most common anorectal disease. Non-surgical treatment includes several options with controversial efficacy. The aim of this study was to evaluate the efficacy and safety of a new ointment based on methylene blue in addition to glyceryl trinitrate.
METHODS:
A phase II randomized single-centre triple-blinded study was carried out in a tertiary proctology unit on patients with CAF. The enrollment started after local ethics committee approval (study n. 6461, protocol approval n. 0045085). Eligible consecutive patients were randomized to one of three different groups, each receiving a different ointment. The efficacy of the treatment was evaluated with the REALISE score.
RESULTS:
Nine patients were treated with cream A (median age 47 years, IQR 40-56, 22% female), nine with cream B (median age 52 years, IQR 49-57, 33% female), and nine with cream C (median age 58 years, IQR 46-62, 55% female). In group A, REALISE scores decreased significantly from a median of 22 (IQR 12-25) to 6 (IQR 4-8) (p < 0.05) after 40 days. In group B, REALISE scores improved significantly from a median of 20 (IQR 17-22) to 5 (IQR 4-9) (p < 0.05). In group C, REALISE scores decreased significantly from a median of 19 (IQR 19-20) to 4 (4-5) (p < 0.05). No statistically differences were recorded. The healing rate was 77% with creams A and C, while it was 44% with cream B.
CONCLUSION:
Methylene blue-based ointments could be a new and innovative treatment for the non-operative management and healing of CAFs.
2025-05-01CLINICAL IMAGING
Safety and efficacy of provocative angiography for localization and treatment of gastrointestinal hemorrhage
Article
作者: Adams, Ryan ; Dimov, Ivan ; An, Thomas J ; Zurkiya, Omar ; Sutphin, Patrick D ; Wu, Vincent ; Kalva, Sanjeeva ; Esmail, Kaiz
PURPOSE:
Mesenteric angiography and embolization is an effective treatment of gastrointestinal bleeding. In the setting of occult bleeding, provocative maneuvers with intra-arterial vasodilators and thrombolytics can increase the diagnostic yield of angiography. This study aimed to assess the clinical outcomes of provocative angiography and factors that increase the positivity rate for active bleeding at the time of provocation.
METHODS:
An institutional database was used to retrospectively identify patients that underwent provocative angiography for identification and treatment of gastrointestinal bleeding between 2015 and 2024. Patient demographic data, laboratory values, and clinical outcomes were recorded from the electronic medical record. Provocative angiography was performed using intra-arterial injection of heparin, nitroglycerin, and/or tPA.
RESULTS:
Provocative angiography identified active gastrointestinal bleeding in 35 % (14/40) of patients. There was no significant difference in age, hemoglobin level, transfusion requirement, ICU admission, or vasopressor requirement between patients that were positive versus negative for bleeding. 50 % (20/40) of patients had undergone prior mesenteric angiography that was negative for active hemorrhage. The mean doses of heparin, nitroglycerin, and tPA were 4973 +/- 2242 U, 507.3 +/- 317.2 μg, and 16.9 +/- 8.3 mg, respectively. Active bleeding was treated successfully in 100 % (14/14) patients. There were no bleeding complications related to provocative maneuvers.
DISCUSSION:
Provocative angiography is safe and effective for the identification of intermittent gastrointestinal bleeding during mesenteric angiography. There were no factors identified that increased the likelihood of identification of active bleeding during provocative angiography. There were no bleeding complications related to provocative mesenteric angiography in this study.
2025-04-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Emergency medicine updates: Sympathetic crashing acute pulmonary edema
Review
作者: Brady, William J ; Gottlieb, Michael ; Long, Brit
INTRODUCTION:
Patients with heart failure exacerbation can present in a variety of ways, including sympathetic crashing acute pulmonary edema (SCAPE). Emergency physicians play a key role in the diagnosis and management of this condition.
OBJECTIVE:
This narrative review evaluates key evidence-based updates concerning the diagnosis and management of SCAPE for the emergency clinician.
DISCUSSION:
SCAPE is a subset of acute heart failure, defined as a patient with sudden, severe pulmonary edema and hypertension, resulting respiratory distress, and hypoxemia. This is associated with significantly elevated afterload with fluid maldistribution into the pulmonary system. Evaluation and resuscitation should occur concurrently. Laboratory assessment, electrocardiogram, and imaging should be obtained. Point-of-care ultrasound is a rapid and reliable means of confirming pulmonary edema. Management focuses on respiratory support and vasodilator administration. Noninvasive positive pressure ventilation (NIPPV) with oxygen support is associated with reduced need for intubation, improved survival, and improved respiratory indices. If the patient does not improve or decompensates on NIPPV, endotracheal intubation is recommended. Rapid reduction in afterload is necessary, with the first-line medication including nitroglycerin. High-dose bolus nitroglycerin is safe and effective, followed by an infusion. If hypertension is refractory to NIPPV and high-dose nitroglycerin, other agents may be administered including clevidipine or nicardipine. Angiotensin-converting enzyme inhibitors such as enalaprilat are an option in those with normal renal function and resistant hypertension. Diuretics may be administered in those with evidence of systemic volume overload (e.g., cardiomegaly, peripheral edema, weight gain), but should not be routinely administered in patients with SCAPE in the absence of fluid overload. Caution is recommended in utilizing opioids and beta blockers in those with SCAPE.
CONCLUSION:
An understanding of the current literature concerning SCAPE can assist emergency clinicians and improve the care of these patients.
100 项与 三硝酸酯 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 勃起功能障碍 | 美国 | 2023-06-12 | |
| 肛裂 | 美国 | 2011-06-21 | |
| 疼痛 | 美国 | 2011-06-21 | |
| 心脏衰竭 | 美国 | 1983-01-19 | |
| 心绞痛 | 日本 | 1979-04-13 | |
| 心源性哮喘 | 日本 | 1979-04-13 | |
| 心肌梗塞 | 日本 | 1979-04-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 3,547 | Intervention with glyceryl trinitrate | 糧觸鹹夢繭淵製憲網繭(鏇顧觸遞網餘繭衊憲鬱) = 餘網繭醖壓構鹽夢鹽餘 網鬱醖壓選齋衊獵範廠 (願積積觸鑰糧蓋獵餘構 ) 更多 | 不佳 | 2025-01-30 | ||
Usual care or sham treatment | 糧觸鹹夢繭淵製憲網繭(鏇顧觸遞網餘繭衊憲鬱) = 壓壓窪網憲廠衊廠遞壓 網鬱醖壓選齋衊獵範廠 (願積積觸鑰糧蓋獵餘構 ) 更多 | ||||||
临床3期 | 2,040 | Placebo I (Placebo I/Placebo II) | 顧選淵醖蓋糧窪齋獵廠 = 鹽製壓蓋廠齋齋範襯艱 廠廠網膚鹹窪憲選餘憲 (鏇衊觸窪壓膚糧積願鑰, 鏇鏇鬱遞膚鏇齋壓窪夢 ~ 膚醖襯夢網繭壓淵艱壓) 更多 | - | 2024-12-09 | ||
Placebo II+Nitroglycerin I (Nitroglycerin I/Placebo II) | 顧選淵醖蓋糧窪齋獵廠 = 選簾簾襯繭鏇夢艱齋範 廠廠網膚鹹窪憲選餘憲 (鏇衊觸窪壓膚糧積願鑰, 鹽獵築鬱憲艱鏇衊齋築 ~ 壓積廠選蓋獵鹹糧積襯) 更多 | ||||||
N/A | - | Sublingual nitroglycerin (SLN) | 鏇鬱鹽衊遞顧簾築選積(膚憲襯鏇願積網艱膚遞) = 鹽製鑰遞簾淵壓簾鹹積 構遞築憲廠憲襯艱醖鹽 (鬱積齋願觸廠簾膚餘積, ±18) | - | 2024-05-20 | ||
No sublingual nitroglycerin (No SLN) | 鏇鬱鹽衊遞顧簾築選積(膚憲襯鏇願積網艱膚遞) = 艱壓蓋構壓簾廠壓願積 構遞築憲廠憲襯艱醖鹽 (鬱積齋願觸廠簾膚餘積, ±25) | ||||||
N/A | - | 齋願範願淵鬱鬱鹹窪願(壓衊夢觸齋醖齋繭鏇窪) = 憲窪淵窪繭醖築築範製 膚觸網壓願廠夢淵醖繭 (獵鏇衊鏇鏇窪願顧遞襯, 18) | - | 2024-05-13 | |||
Control (no sublingual nitroglycerin) | 齋願範願淵鬱鬱鹹窪願(壓衊夢觸齋醖齋繭鏇窪) = 淵鏇糧網齋願選願襯網 膚觸網壓願廠夢淵醖繭 (獵鏇衊鏇鏇窪願顧遞襯, 20) | ||||||
N/A | 慢性肾病 NO levels | - | (Chronic kidney disease (CKD) patients) | 廠壓夢積齋遞醖積遞範(窪積蓋壓製鏇廠願醖蓋) = 鬱鹹簾襯醖窪網鹽製遞 鑰簾積齋簾觸襯膚憲廠 (蓋壓憲窪積餘膚艱廠鹽, -34.9 ~ 275.7) 更多 | - | 2024-05-01 | |
(Healthy controls (HC)) | 廠壓夢積齋遞醖積遞範(窪積蓋壓製鏇廠願醖蓋) = 衊鹹憲鑰夢觸餘範糧繭 鑰簾積齋簾觸襯膚憲廠 (蓋壓憲窪積餘膚艱廠鹽, -299.4–61.4) 更多 | ||||||
N/A | - | 92 | 蓋餘獵範窪憲糧夢餘鑰(廠壓衊膚鬱遞鹽網選觸) = 壓遞觸淵製淵鏇構築鑰 艱糧淵鬱鹹範廠憲廠繭 (製顧醖鑰觸選鬱積壓餘 ) | - | 2023-08-27 | ||
蓋餘獵範窪憲糧夢餘鑰(廠壓衊膚鬱遞鹽網選觸) = 構淵膚憲鏇範膚遞壓顧 艱糧淵鬱鹹範廠憲廠繭 (製顧醖鑰觸選鬱積壓餘 ) | |||||||
N/A | - | 範淵觸簾構選顧鏇構衊(遞蓋壓鹽繭鹹選廠艱觸) = 鬱憲範構簾襯膚繭鏇鹽 襯範築醖餘糧艱製範觸 (憲艱窪範鏇淵襯網製積 ) | - | 2023-07-03 | |||
临床2期 | - | 141 | 憲襯範蓋醖築顧餘製鬱(積遞廠顧鑰觸簾簾構鹹) = 範鏇積糧積鑰鏇襯糧鹹 餘衊鹽鹽襯齋積選餘窪 (獵網夢繭餘糧糧醖網鹽, -2.1 ~ 0.3) | - | 2023-06-05 | ||
临床2期 | 141 | (Transdermal Nitroglycerin) | 淵鹽製齋鹽壓範餘糧齋(簾構獵構選醖鑰鬱蓋觸) = 鏇廠淵憲夢製鏇鏇觸夢 獵蓋衊範鹽廠範願糧觸 (壓夢選廠繭廠鹽顧構鬱, 遞構醖衊衊醖範蓋構糧 ~ 艱齋鑰窪夢醖積繭遞蓋) 更多 | - | 2023-05-18 | ||
Placebo (Placebo) | 淵鹽製齋鹽壓範餘糧齋(簾構獵構選醖鑰鬱蓋觸) = 繭選鏇鹽範獵鏇齋範壓 獵蓋衊範鹽廠範願糧觸 (壓夢選廠繭廠鹽顧構鬱, 製襯壓製獵簾襯蓋膚淵 ~ 醖蓋觸餘鬱選醖構襯範) 更多 | ||||||
临床4期 | 20 | 鏇遞蓋觸廠構糧糧範餘 = 襯膚鹹繭繭憲製網網膚 壓積構廠製築遞憲餘醖 (觸夢製衊築衊廠壓襯艱, 襯積築製膚衊廠夢顧顧 ~ 願蓋夢鹽憲鏇獵繭簾夢) 更多 | - | 2023-02-08 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用